Is Gilead Sciences, Inc. (GILD) a Buy, Sell, or Hold?
Gilead Sciences, Inc.
NASDAQ:GILD
$130.04 USD
-$1.36 (-1.04%)
- Volume
- 5.26M
- Average Volume
- 7.5M
- Market Capitalization
- $161.45B
- P/E Ratio
- 17.53
- Dividend Yield
- 2.48%
- Price Target
- $165.00
- Year High
- $157.29
- Year Low
- $107.75
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.44
- Current Ratio
- $1.97
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Daniel O'Day |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Current Symbol | GILD |
| CUSIP | 375558103 |
| CIK | 0000882095 |
| Web | https://www.gilead.com |
| Phone | 650 574 3000 |
| Currency | USD |
| Employees | 17000 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.94 |
| Payout Ratio | 0.44 |
| Current Ratio | 1.97 |
| Quick Ratio | 1.77 |
| Cash Ratio | 0.80 |
Sales & Book Value
| Annual Sales | $29.44B |
| Price / Sales | 5.43 |
| Cash Flow | 8.24 |
| Price / Cash Flow | 15.78 |
| Price / Book | 6.87 |
Price Target and Rating
| Average Stock Price Forecast | $165.00 |
| High Stock Price Forecast | $180.00 |
| Low Stock Price Forecast | $120.00 |
| Forecast Upside/Downside | -21.19% |
| Consensus Rating | Neutral |
| Rating Score(0-5) | 3 |
| Research Coverage | 58 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $6.78 |
| Trailing P/E Ratio | 17.53 |
| PEG Ratio | 0.32 |
| P/E Growth | 0.32 |
| Net Income | $8.51B |
| Net Margin | 30.99% |
| Pretax Margin | 36.08% |
| Return on Equity | 42.16% |
| Return on Assets | 16.38% |
Financials Score
| AltmanZ Score | 4.72 |
| Piotroski Score | 9.00 |
| Working Capital | 9.16B |
| Total Assets | 56.28B |
| Ebit | 11.26B |
| Market Cap | 163.14B |
| Total Liabilities | 32.85B |
Poll Results
About Gilead Sciences, Inc. (NASDAQ:GILD) Stock
Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations spanning the United States, Europe, and numerous international markets. Its core mission involves discovering, developing, and commercializing innovative medications to address critical health needs. The company's extensive product portfolio encompasses treatments for a variety of severe conditions. For HIV/AIDS, it supplies key therapies such as Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla. In response to the 2019 coronavirus pandemic, Gilead provides Veklury, an injectable drug for intravenous administration. Its offerings for liver diseases include Epclusa, Harvoni, Vosevi, Vemlidy, and Viread. Furthermore, Gilead assists patients battling hematological disorders, va ... rious cancers, and those undergoing cell therapy, through products like Yescarta, Tecartus, Trodelvy, and Zydelig. Other specialized medicines include Letairis, an oral drug for pulmonary arterial hypertension; Ranexa, also an oral medication, for chronic angina; and AmBisome, a liposomal formulation designed to combat serious invasive fungal infections. Gilead Sciences, Inc. actively engages in collaboration agreements with a diverse range of partners to advance its therapeutic pipeline. These include Arcus Biosciences, Inc., Pionyr Immunotherapeutics Inc., Tizona Therapeutics, Inc., Tango Therapeutics, Inc., Jounce Therapeutics, Inc., Galapagos NV, Janssen Sciences Ireland Unlimited Company, Japan Tobacco, Inc., Gadeta B.V., Bristol-Myers Squibb Company, Dragonfly Therapeutics, Inc., and Merck & Co, Inc. The company was founded in 1987 and its corporate headquarters are situated in Foster City, California.
Congo begins trial of Gilead's experimental antiviral for Ebola Bundibugyo
2026-07-14 08:48:12
Researchers in the Democratic Republic of Congo said on Tuesday they have started enrolling participants in a trial testing Gilead Sciences' experimental antiviral obeldesivir as a post-exposure treatment for the ongoing Bundibugyo Ebola outbreak in Congo and Uganda.
2026-07-12 09:23:00
Gilead is seeing success with new oncology and inflammation therapies. The drugmaker went on an acquisition spree this past spring.
Gilead Sciences (GILD) Stock Dips While Market Gains: Key Facts
2026-07-10 19:01:15
In the closing of the recent trading day, Gilead Sciences (GILD) stood at $129.83, denoting a -3.72% move from the preceding trading day.
2 Recession-Resistant Dividend Stocks to Buy and Hold
2026-07-10 12:00:00
You don't need to predict a recession to prepare your portfolio. These two stocks can help.
A Look at Gilead Sciences Inc (GILD) After 5.2% Gain -- GF Value $96.06 vs Price $136.36
2026-07-07 17:17:00
On July 07, 2026, Gilead Sciences Inc (GILD) shares rose 5.2% today, with the current price at $136.36. Over the past year, the stock has seen a 25.2% increase.
2026-07-07 12:30:17
On CNBC's Mad Dash segment on Monday, July 6, 2026, Jim Cramer made one of his most bullish biotech calls in years, arguing that the sector could be entering a new wave of mergers and acquisitions as the regulatory environment becomes more favorable for dealmaking.
Will the Label Expansion of Trodelvy Strengthen GILD's Oncology Portfolio?
2026-07-06 15:41:07
Gilead wins FDA approval to expand Trodelvy into first-line mTNBC, boosting its market reach and strengthening its oncology growth strategy.
Generic Fears Overdone? Gilead Stock Has More Room to Run, Analyst Says
2026-07-06 14:05:23
HSBC upgraded Gilead Sciences Inc. (NASDAQ:GILD) on Monday, citing that the consensus is ‘too pessimistic' in its assumptions of continued decline once dolutegravir faces generics.
Frequently Asked Questions
-
What is the current Gilead Sciences, Inc. (GILD) stock price?
-
Gilead Sciences, Inc.(NASDAQ:GILD) stock price is $130.04 in the last trading session. During the trading session, GILD stock reached the peak price of $157.29 while $107.75 was the lowest point it dropped to. The percentage change in GILD stock occurred in the recent session was --1.04% while the dollar amount for the price change in GILD stock was -$-1.36.
-
GILD's industry and sector of operation?
-
The NASDAQ listed GILD is part of Drug Manufacturers - General industry that operates in the broader Healthcare sector.
-
Who are the executives of GILD?
-
Andrew D. Dickinson | Executive VP & CFO
Daniel O'Day | Chairman & Chief Executive Officer
Johanna Mercier | Chief Commercial & Corporate Affairs Officer
Linda Slanec Higgins | Senior Vice President of Research, Innovation & Portfolio
Jacquie Ross | Senior Vice President of Treasury and Investor Relations -
How many employees does GILD have?
-
Number of GILD employees currently stands at 17000. GILD operates from 333 Lakeside Drive, Foster City, CA 94404, US.
-
Link for GILD official website?
-
Official Website of GILD is: https://www.gilead.com
-
How do I contact GILD?
-
GILD could be contacted at phone #650 574 3000 and can also be accessed through its website. GILD operates from 333 Lakeside Drive, Foster City, CA 94404, US.
-
How many shares of GILD are traded daily?
-
The average number of GILD shares traded daily for last 3 months was 7.5M.
-
What is the market cap of GILD currently?
-
The market value of GILD currently stands at $161.45B with its latest stock price at $130.04